Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize Effects of a Moderate CYP3A Inhibitor on PK of Tazemetostat, Effects of Tazemetostat on PK of CYP2C8 and CYP2C19 Substrates, and Effect of Increased Gastric pH on PK of Tazemetostat in B-cell Lymphoma or Advanced Solid Tumor Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03028103
Recruitment Status : Active, not recruiting
First Posted : January 23, 2017
Last Update Posted : February 22, 2019
Sponsor:
Information provided by (Responsible Party):
Epizyme, Inc.

Brief Summary:
This is a Phase 1, open-label, two-part, safety, PK, and activity study designed to characterize the DDI potential of tazemetostat. Tazemetostat will be taken orally BID continuously in 28-day cycles in both study parts.

Condition or disease Intervention/treatment Phase
Diffuse Large B Cell Lymphoma Primary Mediastinal Lymphoma Mantle Cell Lymphoma Advanced Solid Tumor Marginal Zone Lymphoma Drug: Tazemetostat Drug: Fluconazole Drug: Omeprazole Drug: Repaglinide Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 28 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Multicenter, Two-Part, Phase 1 Study to Characterize the Effects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects With B-cell Lymphoma or Advanced Solid Tumors
Actual Study Start Date : March 27, 2017
Estimated Primary Completion Date : August 2019
Estimated Study Completion Date : September 2019


Arm Intervention/treatment
Experimental: Part A and B

Part A: Subjects enrolled in Part A will receive treatment with oral tazemetostat tablets 400 mg BID for 24 days beginning on Day 1. Subjects will receive fluconazole 400 mg once daily for 4 days starting on Day 16. Tazemetostat 400 mg BID will continue through Day 24. Subjects will then receive tazemetostat 800 mg BID starting on Day 25.

Part B: Subjects enrolled in Part B will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg on Day 1. Administration of tazemetostat 800 mg BID will begin on Day 2. On Day 16, subjects again will receive single oral doses of repaglinide 0.25 mg and omeprazole 20 mg approximately 1 hour after the morning dose of tazemetostat. Subjects also will receive omeprazole 20 mg once daily in the morning on Days 16 through 19.

Drug: Tazemetostat
Tazemetostat is a selective oral small molecule inhibitor of EZH2
Other Name: EPZ-6438, E7438

Drug: Fluconazole
200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat

Drug: Omeprazole
Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.

Drug: Repaglinide
Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.




Primary Outcome Measures :
  1. Part A: Effect of CYP3A inhibition by fluconazole on the PK of tazemetostat (AUC0-t, AUC0-8) [ Time Frame: Days 15 and 19 ]
  2. Part A: Cmax of tazemetostat during co-administration with fluconazole [ Time Frame: Days 15 and 19 ]
  3. Part B: The potential of tazemetostat to inhibit or induce CYP2C8 using repaglinide as a probe substrate (AUC0-t, AUC0-∞) [ Time Frame: Days 1 and 16 ]
  4. Part B: Cmax of repaglinide during co-administration with tazemetostat [ Time Frame: Days 1 and 16 ]
  5. Part B: The potential of tazemetostat to inhibit or induce CYP2C19 using omeprazole as probe a substrate (AUC0-t, AUC0-∞) [ Time Frame: Days 1 and 16 ]
  6. Part B: Cmax of omeprazole during co-administration with tazemetostat [ Time Frame: Days 1 and 16 ]
  7. Part B: Effect of increased gastric pH by omeprazole on the PK of tazemetostat (AUC0-t, AUC0-8) [ Time Frame: Days 16 and 19 ]
  8. Part B: Cmax of tazemetostat during co-administration with omeprazole [ Time Frame: Days 16 and 19 ]

Secondary Outcome Measures :
  1. Incidence of treatment-emergent adverse events as a measure of safety [ Time Frame: Part A: Day 15 predose and through 8 hours post dose. Day 19 predose and through 8 hours post dose Part B: Day 1 through 16 and Day 19 ]
  2. Part A: PK of tazemetostat and its metabolites after administration alone and with fluconazole (AUC0-t, AUC0-8) [ Time Frame: Days 15 and 19 ]
  3. Part A: Tmax of tazemetostat after administration alone with fluconazole [ Time Frame: Days 15 and 19 ]
  4. Part A: t1/2 of tazemetostat after administration alone with fluconazole [ Time Frame: Days 15 and 19 ]
  5. Part A: Cmax of tazemetostat metabolites after administration alone and with fluconazole [ Time Frame: Days 15 and 19 ]
  6. Part A: Tmax of tazemetostat metabolites after administration alone and with fluconazole [ Time Frame: Days 15 and 19 ]
  7. Part A: t1/2 of tazemetostat metabolites after administration alone and with fluconazole [ Time Frame: Days 15 and 19 ]
  8. Part A: Exposure of fluconazole after administration of 400 mg once daily for 4 days (AUC0-8) [ Time Frame: Day 19 ]
  9. Part A: Cmax of fluconazole after administration of 400mg once daily for 4 days [ Time Frame: Day 19 ]
  10. Part A: Tmax of fluconazole after administration of 400mg once daily for 4 days [ Time Frame: Day 19 ]
  11. Part A: The antitumor activity of Tazemetostat will be assessed in patients with diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL) or advanced solid tumors . [ Time Frame: Within 28 days of Day 1, 8 weeks, 16 weeks, 24 weeks ]
  12. Part B: The antitumor activity of Tazemetostat will be assessed in patients with diffuse large B-cell lymphoma (DLBCL), marginal zone lymphoma (MZL), follicular lymphoma (FL) or advanced solid tumors.. [ Time Frame: Within 28 days of Day 1, 8 weeks, 16 weeks, 24 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion criteria

  1. Male or female ≥ 18 years of age at time of consent
  2. Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
  3. Has the ability to understand informed consent and provided signed written informed consent

    Must meet one of the following criteria:

  4. Has histologically confirmed diffuse large B-cell lymphoma (DLBCL), primary mediastinal B-cell lymphoma (PMBCL), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL) and have relapsed or refractory disease following at least two lines of prior standard therapy, including alkylator/anthracycline (unless anthracycline-based chemotherapy is contraindicated)/anti-CD20-based therapy (R-CHOP; rituximab, doxorubicin, cyclophosphamide, vincristine, and prednisolone or prednisone, or equivalent) AND must be considered unable to benefit from intensification treatment with autologous hematopoietic stem cell transplantation (ASCT), as defined by meeting at least one of the following criteria:

    1. Relapsed following, or refractory to, previous ASCT
    2. Did not achieve at least a partial response (PR) to a standard salvage regimen (e.g., R-ICE; rituximab, ifosfamide, carboplatin, etoposide, or R-DHAP; rituximab, dexamethasone, cytarabine, cisplatin)
    3. Ineligible for intensification treatment due to age or significant comorbidity
    4. Ineligible for intensification treatment due to failure to mobilize an acceptable number of hematopoietic stem cells
    5. Refused intensification treatment and/or ASCT Note: Subjects with prior radiotherapy will be included; however, radiotherapy alone will not be considered a separate systemic treatment regimen.

    Note: Subjects with prior radiotherapy will be included; however, radiotherapy alone will not be considered a separate systemic treatment regimen.

    OR

  5. Has histologically confirmed FL, all grades. Subjects must have relapsed/refractory disease following at least 2 standard lines of systemic therapy, including at least 1 anti-CD20-based regimen (eg, rituximab), as well as alkalating agents (eg, cyclophosphamide or bendamustine), and have no curative option with other available therapies OR have a contra-indication to their use. Subjects with prior ASCT may be included. Transformed disease is permitted.

    Note: Subjects with prior radiotherapy will be included; however, radiotherapy alone will not be considered a separate systemic treatment regimen.

    OR

  6. Histologically and/or cytologically confirmed advanced or metastatic solid tumor that has progressed after treatment with approved therapies or for which there are no standard therapies available
  7. Must have evaluable or measurable disease
  8. Has all prior treatment (i.e., chemotherapy, immunotherapy, radiotherapy) related clinically significant toxicities resolve to ≤ Grade 1 per NCI CTCAE, Version 4.03 or are clinically stable and not clinically significant, at time of consent
  9. Time required between the last dose of the latest therapy and the first dose of study drug:

    1. Chemotherapy: cytotoxic At least 21 days
    2. Chemotherapy: nitrosoureas At least 6 weeks
    3. Chemotherapy: non-cytotoxic (e.g., small molecule inhibitor) At least 14 days
    4. Monoclonal antibody (ies) At least 28 days
    5. Non-antibody immunotherapy (e.g., tumor vaccine) At least 42 days
    6. At least 14 days for stereotactic radiosurgery
    7. At least 12 weeks for craniospinal, ≥50% radiation of pelvis, or total body irradiation prior to first dose of study drug
    8. Autologous hematopoietic cell infusion after high dose therapy At least 60 days
    9. Hematopoietic growth factor At least 14 days
  10. Has adequate hematologic (bone marrow [BM] and coagulation factors), renal and hepatic function

    1. Hemoglobin ≥9 g/dL
    2. Platelets ≥75,000/mm3 (≥75 × 10^9/L)
    3. ANC: for patients with lymphoma ≥750/mm3 (≥0.75 × 10^9/L), for patients with advanced solid tumors ≥1,000/mm3 (≥1.0 × 10^9/L),
    4. PT <1.5 ULN
    5. PTT <1.5 ULN
    6. eGFR ≥ 50 mL/min/1.73 m2
    7. Conjugated bilirubin <1.5 × ULN
    8. AST <3 × ULN
    9. ALT <3 × ULN

    NOTE: Laboratory results obtained during screening should be used to determine eligibility criteria. In situations where laboratory results are outside the permitted range, the investigator may retest the subject and the subsequent within range screening result may be used to determine the subject's eligibility.

  11. Has a QT interval corrected by Fridericia's formula (QTcF) ≤480 msec
  12. Subjects with a history of Hepatitis B or C are eligible on the condition that subjects have adequate liver function as defined by the protocol and are hepatitis B surface antigen negative and/or have undetectable HCV RNA.
  13. Male subjects must refrain from donating sperm starting at the planned first dose of investigational product (IP) until 30 days following the last dose of IP
  14. Male subjects with a female partner of childbearing potential must:

    1. Be vasectomized, or
    2. Remain abstinent or use a condom as defined in Section 8.3.8.4.2, starting at the planned first dose of IP until 30 days following the last dose of IP. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, sympto-thermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception.
  15. Female partners of male subjects who are of childbearing potential must also adhere to one of the following:

    1. Placement of an intrauterine device or intrauterine system.
    2. Established use of oral, injected, or implanted hormonal methods of contraception or use of a barrier method of contraception.
    3. Progesterone only oral contraception, where inhibition of ovulation is not the primary mode of action.
  16. Women of childbearing potential or female partners of male subjects must abide by the contraception measures defined by the protocol

Exclusion criteria:

  1. Is pregnant or nursing
  2. Has active central nervous system (CNS) or leptomeningeal metastasis
  3. Has had a prior malignancy other than the malignancies under study Exception: Subject who has been disease-free for 3 years, or a subject with a history of a completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible.
  4. Has thrombocytopenia, neutropenia, or anemia of Grade ≥3 (per CTCAE 4.03 criteria) and any prior history of myeloid malignancies, including myelodysplastic syndrome (MDS).

    NOTE: Bone marrow aspirate/biopsy will be conducted following abnormal peripheral blood smear morphology assessment conducted by the local laboratory. Cytogenetic testing and DNA sequencing will be conducted following an abnormal result of bone marrow aspirate/biopsy.

  5. Has a prior history of T-LBL/T-ALL.
  6. Has had major surgery within 3 weeks prior to enrollment NOTE: Minor surgery (e.g., minor biopsy, central venous catheter placement) is permitted within 3 weeks prior to enrollment.
  7. Is unwilling to exclude grapefruit juice, Seville oranges, and grapefruit from the diet and all foods that contain those fruits from time of enrollment to while on study
  8. Has cardiovascular impairment, history of congestive heart failure greater than NYHA Class II uncontrolled arterial hypertension, unstable angina, myocardial infarction, or stroke within 6 months prior to the planned first dose of tazemetostat; or ventricular cardiac arrhythmia requiring medical treatment
  9. Subjects taking medications that are known potent or moderate inducers/ inhibitors of CYP3A4 (including St. John's Wort)
  10. Has an active infection or recent history (<30 days before study drug administration) requiring systemic treatment
  11. Is immunocompromised, including subjects with known human immunodeficiency virus (HIV) infection
  12. Has known hypersensitivity to any of the components of IP.
  13. Is unable to take oral medications, has a history of surgery that would interfere with the administration or absorption of oral medication, has malabsorption syndrome or any other uncontrolled gastrointestinal condition (e.g., nausea, diarrhea or vomiting) that might impair the bioavailability of IP
  14. Has an uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, or psychiatric illness/social situations that would limit compliance with study requirements.
  15. Is unwilling to adhere to contraception criteria from time of enrollment in study to at least 30 days after last dose of IP.
  16. A history of bleeding (i.e., hemoptysis, hematuria, gastrointestinal blood loss, epistaxis, or others with greater than Grade 1 according to NCI CTCAE Version 4.03) within 1 month prior to beginning therapy or any clinical indications of current active bleeding.
  17. Clinical history, current alcohol (ethanol), or illicit drug use which, in the judgment of the investigator, will interfere with the subject's ability to comply with the dosing schedule and protocol-specified evaluations.
  18. Regular alcohol consumption averaging more than seven drinks/week for women and 14 drinks/week for men within 6 months of screening.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03028103


Locations
Layout table for location information
United States, Arizona
University of Arizona Cancer Center
Tucson, Arizona, United States, 85719
United States, Florida
Moffitt Cancer Center
Tampa, Florida, United States, 33612
United States, New York
Columbia University Medical Center
New York, New York, United States, 10032
Sponsors and Collaborators
Epizyme, Inc.

Layout table for additonal information
Responsible Party: Epizyme, Inc.
ClinicalTrials.gov Identifier: NCT03028103     History of Changes
Other Study ID Numbers: EZH-105
First Posted: January 23, 2017    Key Record Dates
Last Update Posted: February 22, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Lymphoma, B-Cell
Lymphoma, Mantle-Cell
Lymphoma, B-Cell, Marginal Zone
Lymphoma, Large B-Cell, Diffuse
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Lymphoma, Non-Hodgkin
Omeprazole
Fluconazole
Repaglinide
Cytochrome P-450 CYP3A Inhibitors
Anti-Ulcer Agents
Gastrointestinal Agents
Proton Pump Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antifungal Agents
Anti-Infective Agents
14-alpha Demethylase Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP2C9 Inhibitors